UCB SA (EBR:UCB)

Market Cap	48.03B +40.6%
Revenue (ttm)	7.74B +25.8%
Net Income	1.56B +46.3%
EPS	8.03 +46.5%
Shares Out	190.36M
PE Ratio	31.42
Forward PE	27.05
Dividend	1.39 (0.56%)
Ex-Dividend Date	Apr 25, 2025

Volume	615,729
Average Volume	241,611
Open	248.40
Previous Close	248.40
Day's Range	247.80 - 255.60
52-Week Range	129.35 - 289.50
Beta	0.27
RSI	39.45
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 8,600
• Stock Exchange: Euronext Brussels
• Ticker Symbol: UCB

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.